Results 251 to 260 of about 306,022 (339)

Relationship between the parameters of spine sagittal contour and indicators of functional state of the musculoskeletal system in patients with Scheuermann's disease

, 2016
Dniprovska A.V., Kolesnichenko V.A., Fischenko V.O.   +2 more
openalex   +1 more source

Risk factors for relapse in ANCA‐associated vasculitis among patients with relapse after induction of remission with rituximab

Arthritis &Rheumatology, Accepted Article.
Objective To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase ...
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators   +10 more
wiley   +1 more source

Community engagement in health guidelines and other normative products: a methodological review. [PDF]

Bull World Health Organ
Bohren MA, Zahroh RI, Vazquez Corona M, Santos TM, Booth A, Bonet M, Betrán AP, Tunçalp Ö.   +7 more
europepmc   +1 more source

Per‐ and polyfluoroalkyl substances and hand osteoarthritis: data from the Osteoarthritis Initiative

Arthritis &Rheumatology, Accepted Article.
Objective To explore whether biological levels of specific per‐ and polyfluoroalkyl substances (PFAS) and a mixture of PFAS – reflecting the overall effect and accounting for correlations among each PFAS – relate to incident hand osteoarthritis (HOA) and progression.
Jeffrey B. Driban, Lisa B. Rokoff, Bing Lu, Timothy E. McAlindon, Charles B. Eaton, Mary B. Roberts, Diana Mathes, Colleen Lestician, Zhijin Carrie Xu, Zhihua Tina Fan, Shawn P. O'Leary, Ida K. Haugen, Jérémie Sellam, Alice Courties, Abby F. Fleisch   +14 more
wiley   +1 more source

Persistent musculoskeletal pain and its association with future mental distress in adolescents: The Fit Futures study. [PDF]

BMC Public Health
Smedbråten K, Riiser K, Andersen M, Øiestad BE.   +3 more
europepmc   +1 more source

Integrative single cell RNA‐sequencing and spatial transcriptomics uncovers distinct macrophage‐fibroblast cross‐talk in human hip synovium between patients with femoroacetabular impingement and osteoarthritis

Arthritis &Rheumatology, Accepted Article.
Objectives Femoroacetabular impingement (FAI) and synovitis have been recognized as essential factors for developing osteoarthritis (OA) in the hip joints. However, little is known about altered synovial cellular compositions, their associated transcriptomic profiles, and cell‐cell interactions in FAI and hip OA.
Gulzada Kulzhanova, Alexis Klee, Mina Botros, Victoria L. Hansen, John Reuter, Eliya Tazreena Tashbib, Eloise Fadial, Benjamin F. Ricciardi, Brian Giordano, Chia‐Lung Wu   +9 more
wiley   +1 more source

Overload of the lower limbs of firefighters as a result of external conditions. [PDF]

PLoS One
Iwańska D, Tabor P, Urbanik C, Wiszomirska I, Mastalerz A.   +4 more
europepmc   +1 more source

Signs and symptoms of of the musculoskeletal and connective tissue system diseases

, 2017
M. Yabluchansky, L. Bogun, L. Martymianova, O. Bychkova, N. Lysenko   +4 more
openalex   +1 more source

Control of sports exercises and diagnostics of diseases of the musculoskeletal system using hardware and software complex and machine learning algorithm

Mihail Petrov, Andrey Kniga, Dmitry Dyachenko, Artem Dubodelov, Sergey Simakov   +4 more
openalex   +2 more sources

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

Arthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, The TULIP‐SC investigators   +12 more
wiley   +1 more source